Evidence map›Paper›PMID 32916821›Full record

ReviewInternational journal of molecular sciences2020

Smoking and COVID-19: Adding Fuel to the Flame.

Vivek K Kashyap, Anupam Dhasmana, Andrew Massey, Sudhir Kotnala, Nadeem Zafar, Meena Jaggi, Murali M Yallapu, Subhash C Chauhan

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Steroidal lactones fromIn silico pharmacology · 2024
    Article
  7. Article
  8. Article
  9. Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vivek K KashyapDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Anupam DhasmanaDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Andrew MasseyDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Sudhir KotnalaDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Nadeem ZafarDepartment of Pathology, University of Washington, Seattle, DC 98195, USA.
Meena JaggiDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Murali M YallapuDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.ORCID 0000-0002-0073-8828
Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
The University of Texas Rio Grande Valley · USUniversity of Washington · US

Funding

MUC13 Mucin in Colorectal Cancer Health DisparityR01CA204552 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2020
$1.7M
Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
NIH HHS R01 CA204552NIH HHS R01 CA206069NIH HHS R01 CA210192UTRGV UTRGV startup funds and UT star fellow award to SCC
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, an infection caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), has led to more than 771,000 deaths worldwide. Tobacco smoking is a major known risk factor for severe illness and even death from many respiratory infections. The effects of smoking on COVID-19 are currently controversial. Here, we provide an overview of the current knowledge on the effects of smoking on the clinical manifestations, disease progression, inflammatory responses, immunopathogenesis, racial ethnic disparities, and incidence of COVID-19. This review also documents future directions of smoking related research in COVID-19. The current epidemiological finding suggests that active smoking is associated with an increased severity of disease and death in hospitalized COVID-19 patients. Smoking can upregulate the angiotensin-converting enzyme-2 (ACE-2) receptor utilized by SARS-CoV-2 to enter the host cell and activate a 'cytokine storm' which can lead to worsen outcomes in COVID-19 patients. This receptor can also act as a potential therapeutic target for COVID-19 and other infectious diseases. The COVID-19 pandemic sheds light on a legacy of inequalities regarding gender, racial, and ethnic health disparities associated with active smoking, thus, smoking cessation may help in improving outcomes. In addition, to flatten the COVID-19 curve, staying indoors, avoiding unnecessary social contact, and bolstering the immune defense system by maintaining a healthy diet/living are highly desirable.

Indexed as

Coronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSmokingACE-2COVID-19e-cigaretteshooka and cytokine stormSARS-CoV-2smokingvapingα7-nAChR

Identifiers

PMID32916821
PMCPMC7555793
OpenAlexW3084345819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.